The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.
Founded in 1998 by the Estée Lauder family, the ADDF awards grants to leading scientists who are conducting breakthrough drug discovery and early clinical research. The foundation uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage drug development, using any return on investment to support new research.
The ADDF has granted more than $40 million to fund over 310 Alzheimer’s drug discovery programs in academic centers and biotechnology companies in 16 countries. Scientists funded by the ADDF have tested over 30 new drugs in human clinical trials. The ADDF has invested over $9.6 million in 42 biotechnology companies, which have received follow-on commitments of over $1 billion.
Visit www.alzdiscovery.org . Call 212.901.8001.